A Rare Case of Severe Long COVID-19 in Patient with Amyotrophic Lateral Sclerosis

CC BY-NC-ND 4.0 · J Neuroanaesth Crit Care
DOI: 10.1055/s-0042-1755366

Parul Kodan

1   Department of Medicine, All India Institute of Medical Sciences, New Delhi, India

,

Richa Aggarwal

2   Department of Critical and Intensive Care, Jai Prakash Narayan Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India

,

Rakesh Kumar

3   Department of Anaesthesiology, Critical Care and Pain Medicine, All India Institute of Medical Sciences, New Delhi, India

,

2   Department of Critical and Intensive Care, Jai Prakash Narayan Apex Trauma Center, All India Institute of Medical Sciences, New Delhi, India

› Author Affiliations   SFX Search  Permissions and Reprints Introduction

There is growing interest on coronavirus disease 2019 (COVID-19)-associated neurological manifestations and the interplay of COVID-19 in patients with existing neurological illness.[1] We wish to share our rare case of COVID-19-associated neurological manifestations in a patient with amyotrophic lateral sclerosis (ALS). ALS is a neurodegenerative disease with very scarce information suggesting how COVID-19 affects patients with ALS.[2] [3] Case reports of COVID-19 in ALS are handful in literature and none of them highlights the acute deterioration in respiratory status with acute COVID-19 and the subsequent complications of long COVID-19. To the best of our knowledge, this is the first such reported case.

Author Contributions

P.K. and R.A. conceptualized and drafted the letter. R.K. and Satyendra contributed in drafting of the letter.

Publication History

Article published online:
09 December 2022

© 2022. Indian Society of Neuroanaesthesiology and Critical Care. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
References 1 Li X, Bedlack R. COVID-19-accelerated disease progression in two patients with amyotrophic lateral sclerosis. Muscle Nerve 2021; 64 (03) E13-E15 2 Lee S, Arcila-Londono X, Steijlen K, Newman D, Grover K. Case report of ALS patient with COVID-19 infection. Neurology 2021; 96 (15, Supplement): 5032 3 Covis Pharma. Riluzole drug facts. Accessed September 5, 2022 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020599s019lbl.pdf 4 Sorenson EJ. An acute, life-threatening, hypersensitivity reaction to riluzole. Neurology 2006; 67 (12) 2260-2261 5 McGuinness G, Zhan C, Rosenberg N. et al. Increased incidence of barotrauma in patients with COVID-19 on invasive mechanical ventilation. Radiology 2020; 297 (02) E252-E262 6 López Vega JM, Parra Gordo ML, Diez Tascón A, Ossaba Vélez S. Pneumomediastinum and spontaneous pneumothorax as an extrapulmonary complication of COVID-19 disease. Emerg Radiol 2020; 27 (06) 727-730 7 COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry. ClinicalTrials.gov Identifier: NCT04559009. Accessed July 12, 2022 at: https://clinicaltrials.gov/ct2/show/NCT04559009
 

留言 (0)

沒有登入
gif